.

BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Baxter
Dow
QuintilesIMS
Queensland Health
Harvard Business School
Farmers Insurance
Argus Health
Mallinckrodt
Boehringer Ingelheim

Generated: November 19, 2017

DrugPatentWatch Database Preview

Idelalisib - Generic Drug Details

« Back to Dashboard

What are the generic sources for idelalisib and what is the scope of idelalisib patent protection?

Idelalisib
is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Idelalisib has one hundred and forty-nine patent family members in forty-five countries and four supplementary protection certificates in four countries.

One supplier is listed for this compound.

Summary for idelalisib

Pharmacology for idelalisib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► Subscribe ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-002Jul 23, 2014RXYesYes► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
Gilead Sciences Inc
ZYDELIG
idelalisib
TABLET;ORAL205858-001Jul 23, 2014RXYesNo► Subscribe► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: idelalisib

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,518,277 Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
8,653,077Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
8,207,153Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
9,238,070Therapies for hematologic malignancies► Subscribe
8,779,1316-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta► Subscribe
8,993,5835-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
8,623,881Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
8,586,5976-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta► Subscribe
6,667,300 Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
9,487,772Inhibitors of human phosphatidylinositol 3-kinase delta► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: idelalisib

Country Document Number Estimated Expiration
Israel241732► Subscribe
Eurasian Patent Organization025407► Subscribe
Iceland2822► Subscribe
South Korea20160091440► Subscribe
New Zealand592880► Subscribe
Serbia55551► Subscribe
Denmark1278748► Subscribe
European Patent Office1761540► Subscribe
Australia2017200837► Subscribe
Poland358590► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: IDELALISIB

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017 00007Denmark► SubscribePRODUCT NAME: IDELALISIB; REG. NO/DATE: EU/1/14/938 20140924
0867Netherlands► SubscribePRODUCT NAME: IDELALISIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/938 20140919
2017000008Germany► SubscribePRODUCT NAME: LDELALISIB ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/938 20140918
2017004Lithuania► SubscribePRODUCT NAME: IDELALISIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/938 20140918
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Argus Health
Cipla
Farmers Insurance
Cantor Fitzgerald
Merck
Medtronic
US Department of Justice
Chubb
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot